Recently, various executives have taken part in insider selling activity for the stocks of Gilead Sciences, Inc. (NASDAQ:GILD), GoPro Inc (NASDAQ:GPRO), Novavax, Inc. (NASDAQ:NVAX), and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Gilead Sciences, Inc.
Chairman and CEO John C. Martin dumped 150,000 Gilead Sciences shares (3.44% of total stake), valued at $17,876,460, in two transaction dated August 3. Martin now holds 4,364,492 of the company’s shares that are valued at $522,429,692.
EVP of Corporate and Medical Affairs Gregg Alton sold 17,000 shares (11.01% of total stake), valued at $2,024,756, in two transaction on August 3. Alton now holds 154,422 of the company’s shares that are valued at $18,484,313.
EVP of Worldwide Commercial Organization Paul Rutherford Carter disposed of 5,000 shares (9.30% of total stake), valued at $595,920, in two transaction dated August 3. Carter now holds 48,783 of the company’s shares that are valued at $5,839,325.
Finally, Director John Francis Cogan sold 15,000 shares (25.29% of total stake), valued at $1,800,000, on August 3. Cogan now holds 44,309 of the company’s shares that are valued at $5,303,787.
Director Edward Gilhuly indirectly sold 150,000 GoPro shares, valued at $9,633,000, in a transaction dated July 31. Gilhuly now holds indirectly (By Sageview Capital Master, L.P. and Gilhuly Investment Partners LLC) 1,899,893 of the company’s shares. Gilhuly also holds directly 1,463 shares.
SVP of Research and Development Gregory Glenn bought 892 shares worth $2,033 at an average price of $2.28, as reported in the SEC filing on July 31. Following the insider-buying transaction, his stake in Novavax has now grown to 1,158 shares with a value of $13,664.
Chief Financial Officer Barclay Phillips purchased 764 shares, valued $1,741 on July 31. After completion of the transaction, Phillips owns 37,808 shares, worth $446,134.
Regeneron Pharmaceuticals Inc
Director Joseph Goldstein yesterday unloaded 2,000 Regeneron Pharmaceuticals shares (12.50% of total stake), valued at $1,172,000. The shares were sold via automatic sale program. Goldstein now holds 14,000 of the company’s shares that are valued at $8,180,200.